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growing public health problem worldwide. Increasing recogni-
tion of the importance of NAFLD and its association with the
features of the metabolic syndrome has stimulated an interest
in its putative role in the development and progression of chronic
kidney disease (CKD). Accumulating evidence suggests that
NAFLD and CKD share many important cardio-metabolic risk
factors and common pathogenetic mechanisms and that NAFLD
is associated with an increased prevalence and incidence of
CKD. This association appears to be independent of obesity,
hypertension, and other potentially confounding factors, and it
occurs both in patients without diabetes and in those with diabe-
tes. Although further research is needed to establish a deﬁnitive
conclusion, these observations raise the possibility that NAFLD
is not only a marker of CKD but also might play a part in the path-
ogenesis of CKD, possibly through the systemic release of several
pro-inﬂammatory/pro-coagulant mediators from the steatotic/
inﬂamed liver or through the contribution of NAFLD itself to insu-
lin resistance and atherogenic dyslipidemia. However, given the
heterogeneity and small number of observational longitudinal
studies, further research is urgently required to corroborate the
prognostic signiﬁcance of NAFLD for the incidence of CKD, and
to further elucidate the complex and intertwined mechanisms
that link NAFLD and CKD. If conﬁrmed in future large-scale
prospective studies, the potential adverse impact of NAFLD on
kidney disease progression will deserve particular attention,
especially with respect to the implications for screening and
surveillance strategies in the growing number of patients with
NAFLD.
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E-mail address: giovanni.targher@univr.it (G. Targher).Chronic kidney disease (CKD) is a worldwide health problem that
results in high morbidity, mortality, and health care costs. CKD is
deﬁned as a sustained reduction in the glomerular ﬁltration rate
(GFR) or evidence of structural or functional abnormalities of the
kidneys based on urinalysis, biopsy, or imaging [1,2]. Recent data
from the Unites States population-based Third National Health
and Nutrition Examination Survey (NHANES III) reported that
the prevalence of CKD in the United States is approximately
13% [3]. In Europe, the prevalence of CKD is very similar to that
in the United States [1,4]. CKD has many potential causes, which
vary in frequency between different populations. In developed
countries, older age, hypertension, diabetes, obesity, and dyslipi-
demia are consistently associated with CKD [1,2,4–8]. Notably,
CKD is increasingly recognized as a major risk factor not only
for end-stage renal disease but also for cardiovascular disease
(CVD) [2,9,10].
Non-alcoholic fatty liver disease (NAFLD) has reached epi-
demic proportions and is the most common cause of chronic liver
disease in Western countries [11–13]. It comprises a disease
spectrum ranging from simple steatosis to non-alcoholic steato-
hepatitis (NASH) and cirrhosis. NAFLD is strongly associated with
a myriad of important co-morbidities, such as obesity, diabetes,
hypertension, and atherogenic dyslipidemia, and it is now
regarded as the hepatic manifestation of the metabolic syndrome
[11–13]. The prevalence of NAFLD has been estimated to be
between 20% and 30% in the general adult population in Western
countries but this value is much higher among persons who are
obese or have diabetes [11–15].
In recent years, the recognition of the importance of NAFLD
and its strong relationship with clinical traits of the metabolic
syndrome has stimulated a growing interest in the potential
prognostic value of NAFLD for adverse CVD outcomes [14]. Simi-
larly, the possible link between NAFLD and CKD has also attracted
scientiﬁc interest. NAFLD and CKD share many important cardio-
metabolic risk factors and common pathogenic mechanisms, and
both are linked to an increased risk of incident CVD events
[2,9,10,13,14]. Moreover, the presence of pathophysiological
inter-relationships between the liver and the kidney is well
established in humans, and is supported by the presence of the11 vol. 54 j 1020–1029
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hepato-renal syndrome, which may occur in patients with
decompensated cirrhosis, regardless of its etiology.
This review focuses on the rapidly expanding body of clinical
evidence that supports a signiﬁcant association between NAFLD
and the risk of CKD to promote a greater awareness of the need
for a comprehensive surveillance plan in patients with NAFLD.Increased prevalence of risk factors of chronic kidney disease
in patients with NAFLD
Patients with NAFLD, both adults and children, frequently meet
the diagnostic criteria for the metabolic syndrome (i.e., obesity,
hypertension, atherogenic dyslipidemia, and dysglycemia) and,
therefore, have multiple risk factors for CVD [11–15].
Patients with NAFLD also have greater insulin resistance
than control subjects who do not have steatosis, and there is
a near-universal association between NAFLD and insulin resis-
tance, irrespective of obesity [11–14]. Although NAFLD is now
regarded as the hepatic manifestation of the metabolic syn-
drome [11–14], it is important to note that not all patients with
the metabolic syndrome will develop NAFLD and not all patients
with NAFLD have the metabolic syndrome. This may also have
clinical implications in terms of CVD risk assessment in NAFLD
given that the concept of the metabolic syndrome and its prog-
nostic importance for CVD outcomes have repeatedly been chal-
lenged. In particular, there remains debate as to whether or not
the prognostic signiﬁcance of the metabolic syndrome exceeds
the risk associated with the sum of its individuals components
[16,17].
As reviewed in detail elsewhere [18,19], a number of case-
control studies have also shown that NAFLD is associated with
many other emerging and non-traditional CVD risk factors. As
compared with control subjects who do not have steatosis,
patients with NAFLD have signiﬁcantly lower plasma adiponectin
levels, higher plasma inﬂammatory and hemostatic factors, and
higher plasma endothelial dysfunction, and oxidative stress bio-
markers [13–15,18,19].
Several epidemiological studies have shown that the classical
CVD risk factors, such as obesity, diabetes, hypertension, and
dyslipidemia, are also important risk factors for the development
and progression of CKD [1,2,5–8]. Recently, in the Atherosclerosis
Risk in Communities (ARIC) study, it has also been reported that
the metabolic syndrome is associated with an increased risk for
incident CKD over a 9-year period [20]. This risk was independent
of potential confounding factors such as age, sex, race, education,
body mass index, alcohol and tobacco use, pre-existing CVD, and
physical activity. There were strong, graded relationships among
the number of clinical traits of the metabolic syndrome, HOMA-
insulin resistance, or fasting insulin levels and the risk for
incident CKD, suggesting a pathophysiological basis for these
ﬁndings. Moreover, the increased risk for CKD was evident even
after adjusting for hypertension (a potential cause and conse-
quence of kidney disease) and incident diabetes (another known
mediator of CKD) [20]. These observations provide a rationale for
intervention studies that aim to verify whether treating the many
features of the metabolic syndrome can effectively prevent the
development and progression of renal damage.
Finally, and similarly to the associations observed in NAFLD, a
number of observational studies have indicated that CKD is asso-
ciated with decreased adiponectin levels, increased oxidativeJournal of Hepatology 2011stress, elevated systemic inﬂammation, hypercoagulation, and
hypoﬁbrinolysis [5,21–23]. Although most of the human studies
performed to date are observational, and, therefore, causal rela-
tionships cannot be deﬁnitively determined, many of these
emerging risk factors and biomarkers could potentially be impli-
cated in the development and progression of CKD [5,21–23].Increased prevalence of chronic kidney disease in patients
with NAFLD
Several investigators [24–34] have examined the prevalence of
kidney disease in patients with NAFLD (as described in Table 1).
Given the strong association between NAFLD and multiple risk
factors for CKD, it is certainly not surprising that patients with
NAFLD have a remarkably higher prevalence of CKD than do con-
trol subjects without steatosis.
In a large community-based cohort involving approximately
2000 unselected patients with type 2 diabetes, the prevalence
of CKD (deﬁned as estimated GFR 6 60 ml/min/1.73 m2 or overt
proteinuria) was higher among patients with ultrasound-diag-
nosed NAFLD than among those without this disease (15% vs.
9%, p <0.001), independently of traditional risk factors, duration
of diabetes, extent of glycemic control, use of lipid-lowering,
hypoglycemic, anti-hypertensive, and anti-platelet medications,
and components of the metabolic syndrome [24]. The ﬁndings
were similar in a study of adults with type 1 diabetes [25].
In 1361 patients who presented an abnormal oral glucose tol-
erance test on routine screening, patients with ultrasound-diag-
nosed NAFLD had a greater prevalence of microalbuminuria
compared with those who did not have steatosis (19% vs. 6.3%
in patients with pre-diabetes; 32.6% vs. 4.5% in those with newly
diagnosed diabetes; p <0.0001) [26]. Multivariate logistic regres-
sion analysis revealed that NAFLD was associated with the pres-
ence of microalbuminuria independently of several potential
confounders [26].
Large population-based studies that used elevated serum liver
enzyme levels as surrogate markers for NAFLD (and should there-
fore be interpreted with caution) have shown that this disease is
independently associated with an increased prevalence of CKD
[27–29]. For instance, data from the NHANES III study reported
that mildly elevated levels of serum gamma-glutamyltransferase
(GGT) were associated with an increased prevalence of CKD in the
United States adult population after adjusting for demographics,
co-morbidities, alcohol consumption, lipid-lowering medications,
viral hepatitis status, and laboratory measures [27]. These ﬁnd-
ings are at variance with those reported in the Framingham Heart
Study where serum creatinine levels did not change signiﬁcantly
across serum GGT quartiles [30]. However, it is important to note
that estimated GFR is widely accepted as the best overall mea-
sure of kidney function, and that the use of serum creatinine
alone, to distinguish differences across kidney function levels,
can be misleading [4].
Among the few and small studies that used liver biopsy to
diagnose NAFLD [31–34], Yilmaz et al. demonstrated that micro-
albuminuria was independently associated with the histologic
features of NAFLD in a hospital-based sample of 87 nondiabetic
individuals with NAFLD; however, their study lacked a control
group [31]. Manco et al. failed to detect any signiﬁcant differ-
ences in markers of kidney function between overweight/obese
children with NAFLD and age- and sex-matched control childrenvol. 54 j 1020–1029 1021
Table 1. Principal cross-sectional studies of the association between NAFLD and chronic kidney disease.
Investigators Study 
population 
Diagnosis of 
NAFLD  
Study 
measures 
Adjustments 
considered  
Main results  
and risk for prevalent 
CKD in subjects with 
NAFLD versus those 
without – odds ratios 
(95% CI)
 
Targher G et al. 
[24] 
Targher G et al.  
[25] 
Hwang ST et al. 
[26] 
Targher G et al.  
[27] 
Targher G et al.  
[28] 
 
 
Yun KE et al.  
[29] 
 
Lee DS et al.  
[30] 
Community-based 
cohort of 2,103 type 2 
diabetic outpatients 
who did not have 
cardiovascular 
disease, cirrhosis or 
viral hepatitis 
202 type 1 diabetic 
adults who did not 
have secondary 
causes of chronic liver 
disease 
Health-examination 
survey of 1,361 
patients with impaired 
glucose tolerance or 
newly diagnosed 
diabetes (on oral 
glucose tolerance 
test) who did not have 
cardiovascular 
disease, malignancy, 
cirrhosis and viral 
hepatitis 
National Health and 
Nutrition Examination 
Survey (NHANES) 
2001-2006;   
n = 13,188 
 nemow dna nem
National Health and 
Nutrition Examination 
Survey (NHANES) 
2001-2006;  
n = 13,184 
 nemow dna nem
Health-examination 
survey of 37,085 
Korean men and 
women without viral 
hepatitis and 
excessive alcohol 
consumption  
Framingham Heart 
Study; n = 3,451  
 nemow dna nem
Ultrasonography 
Ultrasonography 
Ultrasonography 
Liver enzymes  
(serum GGT) 
Liver enzymes  
(serum bilirubin) 
Liver enzymes  
(serum ALT) 
Liver enzymes  
(serum GGT) 
Estimated GFR 
60 ml/min/1.73 
m2 or overt 
proteinuria 
Estimated GFR 
60 ml/min/1.73 
m2 or urinary 
alb/creat ratio
≥30 mg/g 
 
Urinary 
alb/creat ratio
≥30 mg/g 
 
Estimated GFR 
<60 ml/min/1.73 
m2 or 
alb/creat ratio
n≥30 mg/g 
 
Estimated GFR 
<60 ml/min/1.73 
m2 or 
alb/creat ratio
≥30 mg/g 
 
Estimated GFR
Serum 
creatinine  
Age, sex, BMI, waist 
circumference, hypertension, 
alcohol consumption, diabetes 
duration, hemoglobin A1c, 
LDL-cholesterol, triglycerides, 
smoking, medication use 
(hypoglycemic, anti-
hypertensive, anti-platelet or 
lipid-lowering drugs) 
Age, sex, BMI, systolic blood 
pressure, alcohol 
consumption, diabetes 
duration, hemoglobin A1c, 
triglycerides, and medication 
use  
Age, sex, BMI, waist 
circumference, smoking, 
hemoglobin A1c, triglycerides, 
LDL-cholesterol, liver 
enzymes, insulin resistance, 
and presence of metabolic 
syndrome 
Age, sex, race, smoking, 
alcohol intake, lipid-lowering 
medications, hypertension, 
diabetes, BMI, waist 
circumference, LDL-
cholesterol, HDL-cholesterol, 
triglycerides, glucose, alanine 
aminotransferase, viral 
hepatitis status 
Age, sex, race, BMI, waist 
circumference, smoking, 
alcohol intake, lipid-lowering 
medications, hypertension, 
diabetes, LDL-cholesterol, 
HDL-cholesterol, triglycerides, 
insulin resistance, viral 
hepatitis status 
No adjustments 
No adjustments 
NAFLD associated 
with increased risk of 
prevalent CKD  
Adjusted OR 1.87 
(1.3-4.1) 
NAFLD associated 
with increased risk of 
prevalent CKD  
Adjusted OR 3.29 
(1.2-9.1) 
NAFLD associated 
with increased risk of 
prevalent 
microalbuminuria  
Adjusted OR 3.66 
(1.3-10.2) in patients 
with pre-diabetes 
Adjusted OR 5.47 
(1.01-29.6) in those 
with newly diagnosed 
diabetes 
Elevated serum GGT 
levels associated 
with prevalent CKD  
Adjusted OR 1.44 
(1.2-1.74)  for 
subjects with GGT 
levels in the 4th 
quartile (i.e., GGT 
>39 U/L for men and 
GGT >25 U/L for 
women)
 
Increased total 
bilirubin associated 
with abnormal 
albuminuria  
Adjusted OR 1.26 
(1.03-1.54)  
Subjects with serum 
ALT >40 U/L had 
lower estimated GFR 
than those with 
serum ALT 40 U/L 
No differences  
(continued on next page)
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Table 1 (continued)
Investigators Study 
population 
Diagnosis of 
NAFLD  
Study 
measures 
Adjustments 
considered  
Main results  
and risk for prevalent 
CKD in subjects with 
NAFLD versus those 
without – odds ratios 
(95% CI)
Targher G et al.
[34] 
Yilmaz Y et al.
[31] 
Manco M et al.
[32] 
Yasui K et al.
[33] 
80 patients with 
NASH and 80 age-, 
sex- and BMI-
matched control 
subjects without 
steatosis 
Hospital-based 
sample of 87 NAFLD 
patients 
80 overweight/obese 
children with NAFLD 
and 59 age- and sex-
matched children 
Hospital-based 
sample of 174 NAFLD 
Biopsy 
Biopsy 
Biopsy 
Biopsy 
Estimated GFR 
60 ml/min/1.73 
m2 or 
alb/creat ratio
≥30 mg/g 
24 hrs urinary 
albumin 
excretion rate 
Creatinine 
clearance and 
24 hr urinary 
albumin 
excretion rate 
Estimated GFR 
<60 ml/min/
m2 or 
alb/creat ratio
≥30 mg/g
1.73 
Age, sex, BMI, waist 
circumference, smoking, 
blood pressure, triglycerides, 
insulin resistance 
Age, sex, BMI, blood 
pressure, triglycerides, HDL-
cholesterol, 
aminotransferases, insulin 
resistance 
No adjustments 
Age, sex, BMI, hypertension 
NASH patients had 
lower estimated GFR 
and higher frequency 
of CKD 
Adjusted OR 6.14 
(1.6-12.8)
Microalbuminuria 
associated with the 
severity of NAFLD 
histology (i.e., fibrosis 
stage) 
No differences  
NASH patients had 
higher frequency of
CKD than those with 
simple steatosis. The 
association was 
primarily mediated by
hypertension
ALT, alanine aminotransferase; BMI, body mass index; GGT, gamma-glutamyltransferase; HDL, high-density lipoprotein; LDL, low density lipoprotein; Alb, albumin; Creat,
creatinine. Insulin resistance was estimated by a homeostasis model assessment (HOMA). Glomerular ﬁltration rate (GFR) was estimated by using the Modiﬁcation of Diet
in Renal Disease (MDRD) study equation.
JOURNAL OF HEPATOLOGYwithout steatosis [32]. Recently, we found that patients with his-
tologically deﬁned NASH had moderately decreased estimated
GFR values and a greater frequency of both abnormal albumin-
uria and CKD than did matched control subjects who did not have
steatosis. Notably, as shown in Fig. 1, the histologic severity of0 
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Fig. 1. Adjusted means (±standard deviations) of estimated glomerular ﬁltra-
tion rate (GFR) in relation to the histologic severity of non-alcoholic steato-
hepatitis (i.e., NASH/ﬁbrosis stage increasing from zero to three) in patients
with NASH. p value for the trend is determined bymeans of analysis of covariance.
Data have been adjusted for age, sex, body mass index, waist circumference,
hypertension status, levels of triglycerides, and insulin resistance (as estimated by
homeostasis model assessment). Data are from Targher et al. [34].
Journal of Hepatology 2011NASH (i.e., NASH/ﬁbrosis stage) was associated with decreasing
mean values of estimated GFR independently of traditional CVD
risk factors, insulin resistance, and metabolic syndrome compo-
nents [34]. Larger studies will be needed to conﬁrm the reproduc-
ibility of these results.
Collectively, the published data provide clear evidence that
NAFLD/NASH is associated with a greater prevalence of CKD,
and suggest that NAFLD patients should be considered at
increased risk for the development of CKD. However, the cross-
sectional nature of these studies necessitates caution in inter-
preting the results, and large prospective studies are needed to
determine whether NAFLD may contribute to the development
and progression of CKD.Increased incidence of chronic kidney disease in patients with
NAFLD
The main large prospective studies [35–38] assessing the rela-
tionship between NAFLD (as detected by means of ultrasonogra-
phy or serum liver enzyme measurements) and the incidence of
CKD are described in Table 2.
The Valpolicella Heart Diabetes Study enrolled 1760 type 2
diabetic individuals with normal or near-normal kidney function
who did not have CVD, cirrhosis and viral hepatitis at baseline.
During a mean follow-up of 6.5 years, 547 participants developedvol. 54 j 1020–1029 1023
Table 2. Principal prospective studies of the association between NAFLD and the incidence of chronic kidney disease.
Investigators Study 
population
Length of
follow-up
(years)
Diagnosis of
DLFAN
ydutS
outcomes
Adjustments
deredisnoc
Main Results  
and Risk for incident
CKD in subjects with 
NAFLD versus those 
without – hazard ratios 
(95% CI)
yhpargonosartlU5.6
yhpargonosartlU2.3
semyznereviL51
(serum GGT)
Targher G et al.
[35]
Chang Y et al. 
[36]
Lee DH et al.  
[37]
Ryu S et al.  
[38]
Valpolicella 
Heart Diabetes 
Study; n = 1,760 
type 2 diabetic 
outpatients with 
normal kidney 
function who did 
not have 
cardiovascular 
disease, 
cirrhosis or viral 
hepatitis at 
baseline 
Community-
based cohort of 
8,329 healthy 
men with 
normal kidney 
function and no 
proteinuria at 
baseline 
Coronary Artery 
Risk 
Development in 
Young Adults 
(CARDIA) 
study; n = 2,478 
black and white 
men and 
women  
Estimated GFR 
<60 ml/min/1.73 
m2 or overt 
proteinuria  
Estimated GFR 
<60 ml/min/1.73 
m2 or overt 
proteinuria 
Urinary 
alb/creat ratio
≥30 mg/g 
Sex, age, BMI, waist 
circumference, blood 
pressure, smoking,
diabetes duration, 
hemoglobin A1c, 
triglycerides, HDL-
cholesterol, LDL-
cholesterol, estimated 
GFR, medication use 
(i.e. lipid-lowering, 
hypoglycaemic, anti-
hypertensive, anti-
platelet drugs) 
Age, BMI, alcohol 
consumption, blood 
pressure, smoking, 
fasting glucose, 
estimated GFR, 
triglycerides, HDL-
cholesterol, LDL-
cholesterol, insulin 
resistance or C reactive 
protein 
Age, sex, race, study 
center, education, BMI, 
smoking, alcohol 
consumption, physical 
exercise, hypertension, 
diabetes, triglycerides, 
HDL-cholesterol, LDL-
cholesterol 
NAFLD associated 
with increased risk 
of incident CKD  
Adjusted HR 1.49 
(1.1-2.2) 
NAFLD associated 
with increased risk 
of incident CKD  
Adjusted HR 1.60 
(1.27-2.01) 
Elevated serum 
GGT levels 
associated with 
increased risk of 
incident 
microalbuminuria 
Adjusted HR 4.38 
(1.48-12.9) for 
subjects with GGT 
levels in the 4th
quartile (i.e., 
≥29 U/L) 
Community-based 
cohort of 10,337 
non-diabetic and 
non-hypertensive 
men with normal 
kidney function 
and no proteinuria 
at baseline 
semyznereviL5.2
(serum GGT)
Estimated GFR 
<60 ml/min/1.73
m2 or overt 
proteinuria
Age, BMI, alcohol intake, 
blood pressure, smoking, 
triglycerides, HDL-
cholesterol, LDL- 
cholesterol, uric acid,  
estimated GFR, insulin 
resistance or C reactive 
protein
Elevated serum GGT 
levels associated with 
increased risk of 
incident CKD  
Adjusted HR 1.87 
(1.31-2.67) for subjects 
with GGT levels in the 
4th quartile (i.e., >40 
)L/U04>
BMI, body mass index; GGT, gamma-glutamyltransferase; HDL, high-density lipoprotein; LDL, low density lipoprotein.
Insulin resistance was estimated by a homeostasis model assessment (HOMA). Glomerular ﬁltration rate (GFR) was estimated by using the Modiﬁcation of diet in renal
disease (MDRD) study equation.
Reviewincident CKD (deﬁned as estimated GFR <60 ml/min/1.73 m2 or
overt proteinuria). Multivariate logistic regression analysis
revealed that ultrasound-diagnosed NAFLD was associated with
an increased incidence of CKD, independently of a broad number
of important risk factors and potential confounders [35].
Similarly, Chang et al. [36] followed a community-based
cohort of 8329 healthy Asian men with normal kidney function1024 Journal of Hepatology 2011and no proteinuria at baseline for a mean period of 3.5 years.
During the follow-up, 324 individuals developed incident CKD
(i.e., estimated GFR <60 ml/min/1.73 m2 or overt proteinuria).
Ultrasound-diagnosed NAFLD was associated with an increased
risk of incident CKD independently of traditional risk factors,
insulin resistance, metabolic syndrome components or C-reactive
protein [36].vol. 54 j 1020–1029
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Two large prospective studies using elevated serum liver
enzyme levels as surrogate markers for NAFLD have also shown
that this disease was independently associated with an increased
incidence of kidney disease [36,37]. For instance, in the Coronary
Artery Risk Development in Young Adults (CARDIA) study serum
GGT levels showed a positive dose–response association with
incident microalbuminuria among individuals who had ever been
diagnosed with hypertension or diabetes during 15 years of the
study [37].
It is important to note that the patient cohorts (diabetic in
one, nondiabetic in three) and the deﬁnition of NAFLD used in
the four published prospective studies were heterogeneous and
that the individual outcome measures were not uniform (GFR
reduction or overt proteinuria in three, microalbuminuria in
one), as speciﬁed in Table 2. Moreover, in all these studies, the
authors used an estimated GFR instead of direct GFR measure-
ment to deﬁne CKD. It is known that the Modiﬁcation Diet in
Renal Disease (MDRD) study equation underestimates renal func-
tion in severely obese subjects and demonstrates a greater inac-
curacy in populations without known CKD (or in patients with
early stages of CKD) than in those with kidney disease (i.e.,
patients with stages 3–5 of CKD) [1,2,4]. Nonetheless, current
GFR estimates facilitate the evaluation and management of
CKD, and many scientiﬁc organizations recommend the use of
the MDRD study equation to estimate kidney function in epide-
miologic studies and in clinical practice [2,4,39]. Moreover, the
diagnosis of NAFLD was based on either serum liver enzymes
or ultrasound imaging but was not conﬁrmed by liver biopsy,
which is the gold standard for the diagnosis of NAFLD [11–14];
however, it would be unacceptable to perform routine liver biop-
sies in large epidemiologic studies. Finally, the four published
prospective studies employed varying degrees of baseline adjust-
ments for risk factors of CKD as speciﬁed in Table 2. In particular,
only a few of these studies adjusted their results for important
risk factors such as abdominal obesity or insulin resistance,
which play important roles in the pathogenesis of NAFLD and
CKD. An accurate assessment of abdominal visceral fat and insu-
lin resistance would be particularly important to better under-
stand whether the relationship between CKD and NAFLD is
affected by these two risk factors.
Despite these limitations, the data from the published pro-
spective studies seem to be in favor of a signiﬁcant association
between NAFLD and the risk of incident CKD. However, uncer-
tainty remains as to whether NAFLD poses an independent risk
above and beyond known risk factors. There is a suggestion in
that direction, but studies are too few and methodologically not
rigorous. Additional large-scale prospective studies of a more
extensive panel of known risk factors are needed to draw a ﬁrm
conclusion about any independent hepatic contribution to the
increased risk of CKD observed among patients with NAFLD.
Moreover, because CKD has many potential causes, it will also
be of great interest to deﬁne whether NAFLD may selectively con-
tribute to the pathogenesis of different types of kidney disease.Putative biological mechanisms linking NAFLD and chronic
kidney disease
As described in a previous section of the article, because CKD and
NAFLD share many important cardio-metabolic risk factors, it is
perhaps not surprising that the two diseases are closely associ-Journal of Hepatology 2011ated with one another. Understanding the complex and inter-
twined mechanisms that link NAFLD and CKD is important not
only because of the societal health burden of both diseases but
also because novel insights into the underlying mechanisms
may lead to new strategies to prevent or treat CKD and its asso-
ciated co-morbidities. The presence of pathophysiological inter-
relationships between the liver and the kidney is well established
in humans, and is supported by the presence of the hepato-renal
syndrome, which is characterized by the occurrence of rapid and
progressive renal impairment in patients with decompensated
cirrhosis [40].
From a pathophysiological perspective, there are at least two
key questions that should be addressed. First, is NAFLD associated
with CKD as a consequence of the shared cardio-metabolic risk
factors, or does NAFLD itself contribute to the development of
CKD independently of these factors? Second, is the risk of CKD
also increased in patients with simple steatosis, or is the necro-
inﬂammation characteristic of NASH a necessary ‘‘nephro-toxic’’
stimulus?
Although CKD and NAFLD share common pathophysiological
mechanisms, the understanding of these overlapping pathways
is presently incomplete. The close correlations of NAFLD and
CKD with abdominal obesity and insulin resistance make it extre-
mely difﬁcult to distinguish the precise causal relationships
underlying the increased risk of CKD among patients with NAFLD.
As schematically shown in Fig. 2, the putative underlying
mechanisms that link NAFLD and CKD might originate from the
expanded and inﬂamed visceral adipose tissue, with the liver
functioning as both the target of the resulting systemic abnor-
malities and the source of several molecular mediators that
amplify the kidney damage.
Expanded and inﬂamed visceral adipose tissue releases multi-
ple molecules that are potentially involved in the development of
insulin resistance and kidney damage, including hormones, free
fatty acids (FFA), interleukin (IL)-6, tumor necrosis factor (TNF)-
alpha, and other pro-inﬂammatory cytokines [41,42]. These adi-
pocytokines may be derived from both the adipocytes themselves
and/or from inﬁltrating macrophages [41,42]. The resulting adi-
pose tissue inﬂammation is one of the earliest steps in the chain
of events that leads to systemic insulin resistance, especially in
obese and overweight persons [42,43]. Activation of pro-inﬂam-
matory pathways is mediated by cytokine receptors and pattern
recognition receptors, including toll-like receptors and receptors
for advanced glycation end products, which are gatekeepers of
the innate immune system [42,43]. These pathways converge
on two main intracellular transcription factor signaling path-
ways, namely, the nuclear factor-kB (NF-kB) pathway, which is
activated by the inhibitor of NF-kB kinase beta, and the c-Jun
N-terminal kinase (JNK) pathway [42,43]. Experimental ﬁndings
in mice indicate that JNK-1 activation in adipose tissue may cause
insulin resistance in the liver [44].
Fatty liver results from increased hepatic uptake of FFA
derived mainly from the hydrolysis of adipose-tissue triglycer-
ides (increased because of insulin resistance) but also from die-
tary chylomicrons and hepatic lipogenesis [11–13]. Insulin
resistance is a key factor in the pathogenesis of NAFLD
[11,13,45] and also plays a role in the development of CKD
[5,20–23].
In the presence of increased FFA inﬂux and chronic inﬂamma-
tion, the liver is again both the target of and the contributor to
systemic inﬂammatory changes. Activation of the NF-kB pathwayvol. 54 j 1020–1029 1025
Fig. 2. Schematic representation of potentially causative mechanisms by which NAFLD may contribute to the development and progression of chronic kidney
disease.
Reviewin the liver of NASH patients leads to the increased transcription
of several pro-inﬂammatory genes that amplify systemic chronic
inﬂammation [43–45]. Fatty liver is associated with increased
production of IL-6 and other pro-inﬂammatory cytokines by
hepatocytes and non-parenchymal cells, including Kupffer cells
and hepatic stellate cells [45,46]. The increase in intra-hepatic
cytokine expression results from local activation of the NF-kB
pathway, as mediated by hepato-cellular damage and fat-derived
factors, and it is likely to play a role in the pathophysiology of
NAFLD [43,45] and CKD [5,23].
The possible molecular mediators linking NAFLD and CKD
may include the systemic release of several pathogenic factors
from the steatotic/inﬂamed liver, such as increased reactive oxy-
gen species, plasminogen activator inhibitor-1 (PAI-1), IL-6, C-
reactive protein (CRP), TNF-alpha, transforming growth factor
(TGF)-beta, and other pro-inﬂammatory cytokines (as summa-
rized in Fig. 2). Notably, several case-control studies have shown
that these plasma inﬂammatory, pro-coagulant, and oxidative
stress factors are remarkably higher in patients with NAFLD/
NASH than in those without those conditions [18,19,45–48].
From a pathophysiological perspective, it is important to empha-
size that chronic inﬂammation, enhanced oxidative stress, and
hypercoagulation are increasingly recognized for their role in
the pathogenesis of CKD in animal models [23,49–51]. In partic-
ular, in the context of CKD, generation and metabolism of various
pro-inﬂammatory and anti-inﬂammatory cytokines are dis-1026 Journal of Hepatology 2011turbed. Although the exact mechanisms by which chronic inﬂam-
mation and oxidative stress can damage the kidney are not well
delineated, preliminary evidence in animal models suggests that
a cytokine imbalance may contribute to the pathogenesis of
CKD and its associated co-morbidities through a number of
detrimental pleiotropic effects, such as the activation of various
pro-inﬂammatory pathways, the up-regulation of adhesion mol-
ecules, the induction of endothelial dysfunction and oxidative
stress, and the decrease of adiponectin expression [23,49–51].
Consistent with the hypothesis that liver inﬂammation (or
other liver-derived factors) in NAFLD may play a role in the path-
ogenesis of CKD, Cheng et al. reported that individuals with
chronic hepatitis B virus infection were more likely to develop
end-stage renal disease compared to those who were not infected
with hepatitis B virus [52].
However, as previously reported, other pathophysiological
mechanisms that are not strictly related to liver inﬂammation
may contribute to the development of CKD in patients with
NAFLD. Decreased concentrations of plasma adiponectin, an adi-
pose-secreted cytokine with anti-diabetic and anti-inﬂammatory
properties [53], might represent another potential mechanism
that links NAFLD and CKD. Individuals with NAFLD exhibit signif-
icantly lower plasma adiponectin levels than do healthy controls
without steatosis, and among persons with NAFLD, plasma adipo-
nectin levels are inversely associated with the histologic severity
of NAFLD independently of obesity and other underlying meta-vol. 54 j 1020–1029
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bolic abnormalities [45,48,54,55]. In a comprehensive review of
animal and human studies, Ix et al. have recently suggested the
attractive hypothesis of common underlying mechanisms that
lead to obesity-associated CKD and NAFLD [56]. In their hypoth-
esis, crosstalk occurs between the adipose tissue, kidney, and
liver, orchestrated principally by adiponectin and the liver-
secreted protein fetuin-A. Indeed, higher fetuin-A and lower
adiponectin levels may work in concert to regulate insulin resis-
tance. In the liver and kidney, lower adiponectin levels reduce
activation of the energy sensor 50-AMP activated protein kinase
(AMPK), which is pivotal in directing hepatocytes and podocytes
to compensatory and potentially deleterious pathways that lead
to inﬂammatory and proﬁbrotic cascades culminating in end-
organ damage (i.e., cirrhosis and end-stage renal disease) [56].
Fibroblast growth factor (FGF)-21, a hormone primarily
secreted by the liver, has recently been shown to have beneﬁcial
effects on glucose and lipid metabolism and hepatic steatosis in
various animal models [57]. Preliminary evidence in humans
suggests that hepatic FGF-21 expression is paradoxically
increased in persons with NAFLD and appears to correlate with
liver histopathology [58], and that circulating FGF-21 levels are
increased in patients with advanced CKD and are related to mark-
ers of renal function in healthy individuals [59]. Further studies,
however, are needed to elucidate the role of FGF-21 in the devel-
opment of CKD in patients with NAFLD.
Various other molecules, such as circulating levels of visfa-
tin, leptin, resistin, and aldosterone have been reported to be
increased both in patients with CKD [50,51,60–62] and in those
with NAFLD/NASH [63–66]. Recently, some investigators have
also measured circulating levels of advanced glycation end-
products (AGE) and its soluble receptors (s-RAGE) in patients
with CKD and in those with NAFLD/NASH [67–70]. Plasma lev-
els of AGEs have been found to be increased both in patients
with NAFLD/NASH [67] and in those with CKD [68], whereas
plasma levels of s-RAGE, which may act as a ‘‘decoy’’ to avoid
interaction of RAGE with its pro-inﬂammatory ligands [71],
have been found to be decreased in patients with NASH [69]
but increased in chronic hemodialysis patients [70], possibly
due to decreased renal function, which is a strong determinant
of plasma s-RAGE levels.
All these above-mentioned molecules could potentially also
be implicated in the development and progression of CKD in
patients with NAFLD but further research is needed to better
deﬁne the role and the importance of these molecules in NAFLD.
Finally, there is ample evidence suggesting that NAFLD can
exacerbate hepatic/systemic insulin resistance and promote the
development of atherogenic dyslipidemia [14,43,72–74], which
play important roles in the development and progression of
CKD [5,21–23].
Further experimental studies are needed to deﬁne the major
sources of some pro-inﬂammatory, pro-coagulant, and pro-oxi-
dant mediators (i.e., to determine the relative contributions of
visceral adipose tissue and the liver itself) as well as to reveal
other speciﬁc mechanisms by which NAFLD might contribute to
the pathogenesis of CKD.Conclusions
NAFLD is increasingly diagnosed worldwide and is the most com-
mon cause of chronic liver disease in Western countries [11–13].Journal of Hepatology 2011The increased rates of CKD and CVD are probably among the most
important clinical features associated with NAFLD, and our
knowledge concerning this phenomenon is rapidly evolving.
To date, there is a mounting body of evidence suggesting that
patients with NAFLD have multiple risk factors of CKD and that
NAFLD is associated with an increased prevalence and incidence
of CKD both in patients without diabetes and in those with diabe-
tes (as speciﬁed in Tables 1 and 2).
The underlying mechanisms and the biological plausibility of
these ﬁndings remain speculative. The most plausible explana-
tion for these ﬁndings is that the link between NAFLD and CKD
may be represented by the shared cardio-metabolic risk factors
and the similar pathogenetic mechanisms that link NAFLD and
CKD. However, although further research in this area is needed
to draw a deﬁnitive conclusion, the published data from recent
prospective studies suggest that NAFLD is associated with an
increased risk of incident CKD that is independent of the risk
conferred by traditional risk factors and components of the met-
abolic syndrome. Collectively, these ﬁndings raise the possibility
that NAFLD/NASH not only is a marker of CKD but also might
contribute to its pathogenesis, possibly through the systemic
release of several pathogenic mediators from the steatotic/
inﬂamed liver or through the contribution of NAFLD itself to
hepatic/systemic insulin resistance and atherogenic dyslipidemia
(as summarized in Fig. 2).
The potential clinical implications of these ﬁndings for patient
care are that the detection of hepatic steatosis (NAFLD) by rou-
tine ultrasound examination should alert clinicians to the possi-
ble coexistence of multiple risk factors of CKD and, therefore,
warrant the evaluation and treatment of kidney disease equiva-
lently to the risk for advancing liver disease.
NAFLD and CKD share similar treatment strategies, which are
aimed primarily at reducing insulin resistance and modifying the
associated cardio-metabolic risk factors [11,13,75,76]. Pharmaco-
therapy for NAFLD should probably be reserved for patients with
NASH who are at highest risk for disease progression [11,13]. The
lack of adequately powered randomized controlled trials of sufﬁ-
cient duration and with histological end-points makes it difﬁcult
to provide deﬁnitive recommendations regarding the treatment
of NAFLD/NASH. Current recommendations are limited to weight
reduction, through diet and physical exercise [75], and to the
treatment of individual components of the metabolic syndrome
with the use of therapies that may have beneﬁcial hepatic effects,
including bariatric surgery for obesity, insulin-sensitizing agents
for type 2 diabetes, and drugs directed at the renin-angiotensin
system for hypertension [11,13,76]. To date, there is no convinc-
ing evidence that lipid-lowering agents, including statins, are
beneﬁcial for NAFLD, although there is considerable evidence that
statin therapy is safe [77]. Preliminary evidence also supports a
role for anti-oxidants, anti-cytokine agents, and hepato-protec-
tants [11,76,78]; however, there are insufﬁcient data to either
support or refute the use of these agents as standard therapy
for patients with NAFLD.
Despite the growing evidence that links NAFLD with CKD, it
remains to be deﬁnitively established whether a causal associa-
tion exists. Additional large-scale studies are needed to elucidate
whether ameliorating NAFLD will ultimately prevent or slow the
development and progression of CKD. Moreover, the prognostic
importance of NAFLD in CKD risk stratiﬁcation remains debat-
able. Thus, more research is urgently needed to corroborate a
prognostic value of NAFLD for the incidence of CKD, and tovol. 54 j 1020–1029 1027
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further elucidate the putative underlying mechanisms that link
NAFLD and CKD.
In the interim, from the perspective of clinical practice, it is
important that specialists and practicing clinicians be aware of
the signiﬁcant association between NAFLD and CKD, especially
because of the high and growing prevalence of CKD and NAFLD.
A multidisciplinary approach to the treatment of NAFLD patients,
based on a careful evaluation of related risk factors and monitor-
ing for cardiovascular, kidney, and liver complications, is
warranted. In particular, health care providers who manage
patients with NAFLD (especially those with more advanced stages
of NAFLD) not only should focus on liver disease but also should
recognize the increased risk for CKD and undertake early, aggres-
sive risk factor modiﬁcations.Author contributions
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